Summary Since Last Update: Teen Brain Risk, Hemp Market Crisis, and Appetite Science — February 24, 2026
February 24, 2026 — 93 articles reviewed
This cycle was dominated by two forces pulling in opposite directions: a landmark study on adolescent cannabis and psychiatric risk that received massive media coverage, and an accelerating federal regulatory crisis threatening to eliminate the hemp-derived cannabinoid market by November. Alongside these, rigorous new research on appetite science, minor cannabinoids, and clinical applications for sleep, pain, and alcohol reduction continued to build the evidence base for adult cannabis medicine.
? Adolescent Cannabis Use and Psychiatric Risk
A single large longitudinal study from Kaiser Permanente, UCSF, and USC — tracking 463,396 adolescents through age 26 and published in JAMA Health Forum — received widespread coverage across NPR, Forbes, Medscape, Ground News, Psychology Today, and multiple other outlets this cycle. The findings were consistent and significant: past-year cannabis use between ages 13 and 17 was associated with approximately double the risk of psychotic and bipolar disorder diagnoses, with cannabis use preceding psychiatric diagnoses by roughly two years on average. A separate Swedish population-level study found that adolescent cannabis consumption mirrors alcohol trends, meaning rising overall use drives disproportionate heavy use among the most vulnerable youth. None of this undermines the case for adult medical cannabis, but it makes the case for youth prevention, age-appropriate restrictions, and psychiatric screening unassailable — the developing brain is not the adult brain, and our policies must reflect that distinction. Clinicians should screen every young patient for age of first use, family psychiatric history, and frequency of consumption before making any cannabinoid recommendation.
- #78A huge study finds a link between cannabis use in teens and psychosis later – NPR
- #78Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape
- #78Cannabis Use by Teenagers Doubles Their Risk of Developing Psychotic and Bipolar Disorders
- #78Adolescent Cannabis Use Linked to Doubling Risk of Psychotic and Bipolar Disorders
- #78Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Use Cannabis
- #78When Legalization Meets Reality: High-THC Cannabis and Psychosis Risk
- #75A huge study finds a link between cannabis use in teens and psychosis later – KUOW
- #75Teenage Cannabis Users Twice as Likely as Non-Users to Develop Psychosis
- #75Do anything, become nothing – The Morning News
- #72A huge study finds a link between cannabis use in teens and psychosis later – WBAA
- #72Teens Who Use Cannabis Face Higher Risk Of Mental Disorders, Study Finds – Forbes
- #72420 with CNW — Study Links Psychiatric Disorders to Adolescent Cannabis Use
- #65Teen Cannabis Use Mirrors Alcohol Consumption Trends – Mirage News
- —Study: Teen Cannabis Use Linked to Double Psychosis Risk – Ground News
- —Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Reported Cannabis Use
- —Teens Using Weed Have Doubled Risk For Psychosis, Bipolar Disorder
? The November 2026 Hemp Ban: An Industry and Patient Access Crisis
The approaching November 12, 2026 federal deadline is shaping up to be the most consequential regulatory event in hemp history, and this cycle’s coverage made the scale of disruption unmistakably clear. The 2026 Farm Bill draft replaces the delta-9-only threshold with a total THC standard, reclassifying delta-8, THCA flower, HHC, and similar compounds as Schedule I — while a 0.4mg THC per-container cap would effectively ban the entire hemp beverage market and threaten even CBD products labeled “THC-free.” The FDA has already missed its congressionally mandated deadline to publish cannabinoid classification lists, enforcement mechanisms remain unclear per the Congressional Research Service, and hemp farmers face the impossible decision of planting crops that may be criminalized before harvest. Patients who rely on affordable hemp-derived CBD — particularly in states without medical cannabis programs — face abrupt disruptions in care with no federal transition plan in place. This is not a theoretical risk; it is an operational countdown that clinicians and patients need to prepare for now.
- #72Patients Who Rely on Hemp-Derived CBD Face ‘Abrupt Disruptions in Care
- #65Are My THC Gummies Going Away? – Science Friday
- #52Key Congressional Committee Set To Vote On Delaying Federal Hemp THC Ban Next Week
- #45Federal Hemp Ban Could Sweep Up Even ‘THC-Free’ CBD Products
- #152026 Farm Bill Removes 0.3% Delta-9 THC Threshold, Inserts Total THC Standard
- #15Hemp Beverage Companies Face Existential Threat Under 0.4mg THC Container Limit
- #15Hemp Beverage CEO: Even Legal Gummies Would Be Illegal to MAKE Under Container Rules
- #15FDA Misses Congressionally Mandated Deadline to Publish Cannabinoid Lists
- #15Congressional Research Service: Enforcement of Hemp Ban ‘Remains Unclear
- #15HEMP Act Industry Reactions: ‘No One Will Grow a Crop That Might Be Illegal in November
- #15Colorado Hemp Farmers Warn New Federal THC Rules Will ‘Devastate’ the Industry
- #15Legal Analysis: Hemp Retailers Face ‘Existential Threat,’ Possible Closure or Forced Pivots
- #15Top Issues in the Cannabis Industry for 2026: Banking, Hemp Redefinition, and Market Contraction
- #152026 Farm Bill Draft Would Reduce Regulatory Burdens for Industrial Hemp Producers
- #15Oregon Proposes 17% Tax on Hemp-Derived Cannabinoid Products in 2026 Session
Have thoughts on this? Share it:
